Published in Biochem J on May 01, 1992
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest (1998) 2.02
Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol (1995) 1.98
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am J Pathol (2002) 1.78
Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer (1999) 1.61
Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J (1999) 1.45
Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41
Selective regulation of MMP and TIMP mRNA levels in tree shrew sclera during minus lens compensation and recovery. Invest Ophthalmol Vis Sci (2005) 1.40
Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis (1995) 1.27
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci U S A (2002) 1.24
Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am J Respir Cell Mol Biol (2007) 1.19
MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis (1997) 1.19
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis (1997) 1.16
Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J (1995) 1.14
TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J (2003) 1.13
Matrix metalloproteases and lung disease. Thorax (1994) 1.13
Specialized podosome- or invadopodia-like structures (PILS) for focal trabecular meshwork extracellular matrix turnover. Invest Ophthalmol Vis Sci (2008) 1.09
Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation (1998) 1.01
The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol (2002) 1.00
Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology (2000) 1.00
The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem J (1994) 1.00
The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3. Matrix Biol (2009) 0.97
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96
Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP). Biochem J (1996) 0.94
Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J (1995) 0.94
Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem (2010) 0.93
Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis (1997) 0.92
Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis (1997) 0.92
Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation. Alcohol Clin Exp Res (2013) 0.91
Clinically relevant doses of lidocaine and bupivacaine do not impair cutaneous wound healing in mice. Br J Anaesth (2010) 0.87
17beta-estradiol inhibits wound healing in male mice via estrogen receptor-alpha. Am J Pathol (2010) 0.85
Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation. Biochem J (1994) 0.83
MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem J (2006) 0.81
Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate. Inflammation (1998) 0.79
Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. Biochem J (2003) 0.78
Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Biochem J (1996) 0.75
Control and inhibition analysis of complex formation processes. Theor Biol Med Model (2012) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol (1987) 58.68
Maturation of the head of bacteriophage T4. I. DNA packaging events. J Mol Biol (1973) 33.51
Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science (1981) 23.67
The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol (1988) 5.84
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem (1989) 5.64
H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem (1988) 4.06
A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett (1992) 2.88
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
The collagenase gene family in humans consists of at least four members. Biochem J (1988) 2.45
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res (1990) 2.40
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J (1989) 1.89
The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis (1990) 1.80
Metalloproteinases from rabbit bone culture medium degrade types IV and V collagens, laminin and fibronectin. Biochem J (1981) 1.62
Fragments of human fibroblast collagenase. Purification and characterization. Biochem J (1989) 1.55
An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. Biochem J (1981) 1.52
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 1.41
Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J Biol Chem (1991) 1.40
Monoclonal antibodies to human fibroblast procollagenase. Inhibition of enzymatic activity, affinity purification of the enzyme, and evidence for clustering of epitopes in the NH2-terminal end of the activated enzyme. Biochemistry (1988) 1.30
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta (1991) 1.28
Characterization of the procollagen IV cleavage products produced by a specific tumor collagenase. J Biol Chem (1984) 1.28
Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. J Cell Sci (1991) 1.26
Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. Biochem J (1991) 1.24
Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler (1991) 1.24
Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J Biol Chem (1991) 1.19
Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem (1991) 1.18
The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem (1991) 1.08
Human fibroblast stromelysin catalytic domain: expression, purification, and characterization of a C-terminally truncated form. Biochemistry (1991) 1.02
Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16. Genomics (1990) 1.00
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 3.97
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
Structure of human factor VIII. Nature (1984) 3.29
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett (1992) 2.88
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry (1986) 2.77
Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J (1987) 2.54
Influence of the codon following the AUG initiation codon on the expression of a modified lacZ gene in Escherichia coli. EMBO J (1987) 2.46
The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 2.19
Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry (1986) 2.14
A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem (1992) 1.85
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem (1998) 1.65
Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem (2000) 1.56
Percutaneous ostomy dilation: a technique for dilating the closed percutaneous endoscopic gastrostomy sites and reinserting gastrostomies. Gastrointest Endosc (1989) 1.54
Elevated plasma stromelysin levels in arthritis. J Rheumatol (1994) 1.54
Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem (1998) 1.43
Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem (1995) 1.41
Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 1.41
Regulation of matrix metalloproteinase activity. Ann N Y Acad Sci (1994) 1.39
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry (1993) 1.36
Supracrystallographic resolution of interactions contributing to enzyme catalysis by use of natural structural variants and reactivity-probe kinetics. Biochem J (1988) 1.35
Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem (1994) 1.34
Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol (1995) 1.30
The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res (1989) 1.30
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta (1991) 1.28
In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood (1994) 1.26
Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler (1991) 1.24
Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem (1994) 1.23
Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem (1999) 1.23
Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci (2000) 1.21
Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci (1999) 1.20
Metalloproteinases and tissue damage. Br J Rheumatol (1991) 1.18
Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. Biochemistry (1994) 1.18
Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin. Virology (1987) 1.18
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Substrate-derived two-protonic-state electrophiles as sensitive kinetic specificity probes for cysteine proteinases. Activation of 2-pyridyl disulphides by hydrogen-bonding. Biochem J (1987) 1.17
Selective uncoupling of RGS action by a single point mutation in the G protein alpha-subunit. J Biol Chem (1998) 1.15
The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci (1994) 1.10
RGS7 is palmitoylated and exists as biochemically distinct forms. J Neurochem (2000) 1.05
Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J (1999) 1.05
Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol (1998) 1.04
Molecular cloning and nucleotide sequence of rat lingual lipase cDNA. Nucleic Acids Res (1985) 1.03
Streptomyces viridochromogenes spore germination initiated by calcium ions. J Bacteriol (1980) 1.03
Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology (1995) 1.03
Restriction fragment length polymorphism analysis and assignment of the metalloproteinases stromelysin and collagenase to the long arm of chromosome 11. Genomics (1988) 1.02
NMR structure of free RGS4 reveals an induced conformational change upon binding Galpha. Biochemistry (2000) 1.00
The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem (1999) 0.99
Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix (1990) 0.99
Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue. Matrix Biol (1998) 0.99
Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1. Biochemistry (1994) 0.98
Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem (1993) 0.98
Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J (1999) 0.97
Regional distribution of regulators of G-protein signaling (RGS) 1, 2, 13, 14, 16, and GAIP messenger ribonucleic acids by in situ hybridization in rat brain. Brain Res Mol Brain Res (2001) 0.96
Distribution of heterotrimeric G-protein beta and gamma subunits in the rat brain. Neuroscience (1998) 0.96
Extracellular matrix and matrix metalloproteinases in sciatic nerve. J Neurosci Res (2003) 0.95
Human platelets as a model for the binding and degradation of thrombopoietin. Blood (1997) 0.95
The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett (1996) 0.95
Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J (1995) 0.94
Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn (1999) 0.93
Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans (1994) 0.93
Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis (1997) 0.92
Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett (1997) 0.92
Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer (1995) 0.91
Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry (1994) 0.90
Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol (1999) 0.90
Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol (1999) 0.89
Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res (1989) 0.89
RGS7 attenuates signal transduction through the G(alpha q) family of heterotrimeric G proteins in mammalian cells. J Neurochem (1998) 0.88
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry (1992) 0.88
Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone. Ann N Y Acad Sci (1999) 0.88